OBJECTIVES: Cisplatin is a chemotherapeutic agent which is widely used and studied for multiple cancer types; however certain types of toxicity (ototoxicity, nephrotoxicity and neurotoxicity) are associated with Cisplatin.  Preclinical studies, performed on human testicular cancer cell lines, have indicated that combining Cisplatin with a Src Inhibitor (KX1-004) may significantly mitigate toxicity related damage.  To utilize the results from preclinical studies examining the benefit of combining Cisplatin with KX1-004 in conjunction with cost of illness estimates from the literature to estimate the potential economic benefits which could result from KX1-004 utilization. METHODS: Data from preclinical studies examining the toxicity limiting efficacy of KX1-004 was combined with clinical and economic data from the literature with respect to the estimated cost of healthcare resources related to the specified toxic effects.  This efficacy and costing information was combined within a decision tree model to estimate the potential cost savings. RESULTS: The preclinical data indicates that KX1-004 may have a protective effect with respect to the neurotoxic, nephrotoxic (22% less damage) and ototoxic (82% less damage) effects. The Src inhibitor, when used alone and in conjunction with Cisplatin, exhibited the potential to slow tumor growth and maintain overall body mass.  The economic modeling resulted in a potential per patient cost savings of $1633 resulting from mitigation of the ototoxic and nephrotoxic effects. CONCLUSIONS: Recent research has indicated that Cisplatin should be considered as a component of the standard therapy regimen for certain cancer types; however toxicity remains a significant concern.  When Cisplatin is used within a regimen which includes KX1-004, the benefits may include decreased damage due to toxicity and an improvement in quality of life.  The Src inhibitor may also provide a survival benefit by enabling patients to remain on a regimen which includes Cisplatin.